At the 2025 Taiwan Society for Immunotherapy of Cancer (TSITC) Summer Meeting,
OBI Pharma CEO Dr. Heidi Wang presented on:
📌Insights from US FDA rejection letters (CRLs)
📌Principles and key considerations in drug development
#OBIPharma #ADCs #TSITC2025 #DrugDevelopment #PrecisionMedicine #OBI902